ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2022. The put-call ratio across all filers is 0.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $87 | -39.6% | 88,984 | -14.1% | 0.00% | – |
| Q2 2023 | $144 | -43.5% | 103,648 | -35.4% | 0.00% | – |
| Q1 2023 | $255 | -74.9% | 160,427 | -1.6% | 0.00% | – |
| Q4 2022 | $1,017 | -99.6% | 163,021 | +291.0% | 0.00% | – |
| Q3 2022 | $280,000 | +57.3% | 41,696 | +48.5% | 0.00% | – |
| Q2 2022 | $178,000 | +9.2% | 28,079 | -19.9% | 0.00% | – |
| Q1 2022 | $163,000 | -83.0% | 35,062 | -81.7% | 0.00% | – |
| Q4 2021 | $960,000 | +64.1% | 191,396 | +293.8% | 0.00% | – |
| Q3 2021 | $585,000 | -19.4% | 48,606 | +41.7% | 0.00% | – |
| Q2 2021 | $726,000 | -31.9% | 34,306 | -9.8% | 0.00% | -100.0% |
| Q1 2021 | $1,066,000 | -26.3% | 38,020 | -31.6% | 0.00% | 0.0% |
| Q4 2020 | $1,446,000 | +227.9% | 55,625 | +369.0% | 0.00% | – |
| Q3 2020 | $441,000 | -95.4% | 11,861 | -93.6% | 0.00% | -100.0% |
| Q2 2020 | $9,502,000 | +68.1% | 185,193 | +3.3% | 0.01% | +75.0% |
| Q1 2020 | $5,653,000 | -31.0% | 179,308 | +30.6% | 0.00% | -20.0% |
| Q4 2019 | $8,188,000 | +541.2% | 137,313 | +294.5% | 0.01% | +400.0% |
| Q3 2019 | $1,277,000 | -35.9% | 34,807 | -18.7% | 0.00% | 0.0% |
| Q2 2019 | $1,991,000 | +202.6% | 42,802 | +161.1% | 0.00% | – |
| Q1 2019 | $658,000 | -29.2% | 16,394 | -18.9% | 0.00% | – |
| Q4 2018 | $929,000 | -66.7% | 20,208 | -67.8% | 0.00% | -100.0% |
| Q3 2018 | $2,786,000 | +130.8% | 62,778 | +103.9% | 0.00% | +100.0% |
| Q2 2018 | $1,207,000 | -69.2% | 30,787 | -43.2% | 0.00% | -66.7% |
| Q1 2018 | $3,918,000 | -15.6% | 54,180 | -23.1% | 0.00% | -25.0% |
| Q4 2017 | $4,641,000 | +1127.8% | 70,497 | +835.1% | 0.00% | – |
| Q3 2017 | $378,000 | -94.7% | 7,539 | -95.1% | 0.00% | -100.0% |
| Q2 2017 | $7,170,000 | +827.6% | 154,906 | +608.1% | 0.01% | +700.0% |
| Q1 2017 | $773,000 | +284.6% | 21,875 | +35.4% | 0.00% | – |
| Q4 2016 | $201,000 | +4925.0% | 16,152 | +5794.9% | 0.00% | – |
| Q3 2016 | $4,000 | 0.0% | 274 | -29.4% | 0.00% | – |
| Q2 2016 | $4,000 | +33.3% | 388 | +106.4% | 0.00% | – |
| Q1 2016 | $3,000 | -91.9% | 188 | -88.8% | 0.00% | – |
| Q4 2015 | $37,000 | -95.9% | 1,675 | -95.7% | 0.00% | -100.0% |
| Q3 2015 | $904,000 | -34.4% | 39,383 | +131.6% | 0.00% | 0.0% |
| Q2 2015 | $1,378,000 | -29.2% | 17,003 | -19.6% | 0.00% | -50.0% |
| Q1 2015 | $1,945,000 | +5302.8% | 21,149 | +2244.7% | 0.00% | – |
| Q4 2014 | $36,000 | -7.7% | 902 | -45.4% | 0.00% | – |
| Q3 2014 | $39,000 | -26.4% | 1,651 | -53.0% | 0.00% | – |
| Q2 2014 | $53,000 | +29.3% | 3,516 | +28.5% | 0.00% | – |
| Q1 2014 | $41,000 | +4000.0% | 2,737 | +2583.3% | 0.00% | – |
| Q4 2013 | $1,000 | -85.7% | 102 | -70.9% | 0.00% | – |
| Q3 2013 | $7,000 | – | 350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |